A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms BERENICE
- Sponsors Roche
- 16 Mar 2021 According to a Roche media release, based on data from (NeoSphere, TRYPHAENA, BERENICE, CLEOPATRA ) trials, the Health Canada has granted market authorization to Perjeta (pertuzumab for injection) as a neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive)
- 04 Oct 2020 This trial is completed in France (Global End Date: 25 Aug 2020), according to European Clinical Trials Database record.
- 18 Sep 2020 Status changed from active, no longer recruiting to completed.